Scil Proteins
Halle-neustadt
About Scil Proteins
Scil Proteins is a biopharmaceutical company discovering and developing Affilin® molecules and working with industry partners in the development and manufacture of protein therapeutics and diagnostics. Affilin® molecules are therapeutics and diagnostics based on a scaffold derived from the human protein Ubiquitin to form highly stable molecules with strong binding specificity and low immunogenicity. Scil Proteins' discovery platform is a fully patent protected screening technology for the identification of target-specific Affilin® molecules using advanced selection systems. Scil Proteins has generated a pipeline of Affilin® therapeutics targeting cancer and other therapeutic areas. It also offers the technology to the industry for collaborative discovery and development partnerships. With a longstanding expertise in protein production and development, Scil Proteins also offers GMP contract biomanufacturing and process development to biotech and pharma companies. Scil Proteins is a well-established private company located in Halle, Germany.
Company Facts
- Operating status: Closed
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Estimated revenue: $1K – $10K
- Total funding: $33.1M
- Last round: Series Unknown (Feb 2011)
- Website: scilproteins.com
- Phone: +49 345/27996330
Industries & Categories
Biotechnology, Health Diagnostics, Manufacturing, Therapeutics
Canonical: https://fsome.com/organization/scil-proteins-2831273 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.